US Industrials and Biotech Beat: Arrow Electronics 39% Sales Growth, Iovance TIL Therapy Momentum, Aspen Aerogels Surpasses

The Quick Take

• Arrow Electronics (ARW) Q3 GAAP EPS $6.17 on 39% sales growth — strong component demand and ECS segment momentum drive consensus beat
• Iovance Biotherapeutics (IOVA) Q3 beats estimates as TIL (tumor-infiltrating lymphocyte) therapy commercialisation gains clinical traction
• Aspen Aerogels (ASPN) Q3 beats analyst estimates with revenue growth — aerogel insulation demand driven by EV battery thermal management

Arrow Electronics (NYSE: ARW), one of the world's largest electronic components and enterprise computing solutions distributors, delivered a standout Q3 2026 result with GAAP EPS of $6.17 and revenue growing approximately 39 percent year-over-year. The revenue acceleration reflects strong component demand across Arrow's global customer base — a signal of recovering inventory correction cycles in the semiconductor distribution channel and broadening electronic manufacturing activity in both consumer and industrial end markets. Arrow's ECS (Enterprise Computing Solutions) segment, which serves IT value-added resellers with server, storage, and cloud infrastructure products, also contributed meaningfully, riding the data centre upgrade cycle that has been a consistent demand driver across the technology distribution sector.

Iovance Biotherapeutics (NASDAQ: IOVA) beat Q3 estimates as the company's commercial launch of its tumor-infiltrating lymphocyte (TIL) therapy continued to exceed initial commercial ramp expectations. TIL therapy — which involves extracting a patient's own cancer-fighting T cells, multiplying them outside the body, and re-infusing them to fight advanced solid tumours — represents a significant advance in personalised oncology. Iovance's Lifileucel, the first FDA-approved TIL cell therapy, is in the early commercial stages, and Q3 results reflecting a beat suggest that treatment centre capacity, insurance reimbursement coverage, and patient referral networks are expanding faster than initial post-approval projections. The shares rose on the Q3 result, validating investor expectations of commercial momentum.

Aspen Aerogels (NYSE: ASPN) reported Q3 results that beat analyst estimates with revenue growth — driven primarily by demand for its aerogel insulation products in electric vehicle battery thermal management. Aspen's PyroThin aerogel blankets are used by major EV manufacturers as thermal runaway protection between battery cells, a safety-critical application that has no easy substitute. The commercial relationship with General Motors' Ultium battery platform has been a primary growth driver, and the Q3 beat likely reflects continued shipment volume growth as GM and other OEMs scale EV production. The result reinforces Aspen's positioning at the intersection of EV battery safety and advanced materials — two high-conviction secular growth themes.

Synthesized from 4 sources covering Iovance Biotherapeutics (IOVA), Arrow Electronics (ARW), and Aspen Aerogels (ASPN) Q3 2026 earnings.